Duke University, Department of Biomedical Engineering, Durham, North Carolina 27708-0281, USA.
J Biomed Opt. 2010 Jan-Feb;15(1):018002. doi: 10.1117/1.3302811.
We describe the potential of 5-aminolevulinic acid (ALA)-induced protoporphyrin IX (PpIX) fluorescence as a source of contrast for margin detection in commonly diagnosed breast cancer subtypes. Fluorescence intensity of PpIX in untreated and ALA-treated normal mammary epithelial and breast cancer cell lines of varying estrogen receptor expression were quantitatively imaged with confocal microscopy. Percentage change in fluorescence intensity integrated over 610-700 nm (attributed to PpIX) of posttreated compared to pretreated cells showed statistically significant differences between four breast cancer and two normal mammary epithelial cell lines. However, a direct comparison of post-treatment PpIX fluorescence intensities showed no differences between breast cancer and normal mammary epithelial cell lines due to confounding effects by endogenous fluorescence from flavin adenine dinucleotide (FAD). Clinically, it is impractical to obtain pre- and post-treatment images. Thus, spectral imaging was demonstrated as a means to remove the effects of endogenous FAD fluorescence allowing for discrimination between post-treatment PpIX fluorescence of four breast cancer and two normal mammary epithelial cell lines. Fluorescence spectral imaging of ALA-treated breast cancer cells showed preferential PpIX accumulation regardless of malignant phenotype and suggests a useful contrast mechanism for discrimination of residual cancer at the surface of breast tumor margins.
我们描述了 5-氨基酮戊酸(ALA)诱导的原卟啉 IX(PpIX)荧光作为常见诊断的乳腺癌亚型中边缘检测的对比源的潜力。用共聚焦显微镜对未经处理和经 ALA 处理的不同雌激素受体表达的正常乳腺上皮和乳腺癌细胞系中的 PpIX 荧光强度进行定量成像。与预处理细胞相比,后处理细胞在 610-700nm 范围内(归因于 PpIX)的荧光强度积分的百分比变化在四种乳腺癌和两种正常乳腺上皮细胞系之间显示出统计学上的显著差异。然而,由于内源性黄素腺嘌呤二核苷酸(FAD)荧光的干扰,直接比较乳腺癌和正常乳腺上皮细胞系的后处理 PpIX 荧光强度没有差异。临床上,获得预处理和后处理图像是不切实际的。因此,光谱成像是一种去除内源性 FAD 荧光影响的方法,允许区分四种乳腺癌和两种正常乳腺上皮细胞系的后处理 PpIX 荧光。ALA 处理的乳腺癌细胞的荧光光谱成像显示,无论恶性表型如何,PpIX 都优先积累,这表明这是一种用于区分乳腺癌肿瘤边缘表面残留癌症的有用对比机制。